FDA Clearance Tracker · P110020
COBAS 4800 BRAF V600 MUTATION TEST
Last checked: Nov 20, 2026Latest source record: Aug 17, 2011 (this decision)Source: openFDAMethods & limitations
Decided
Aug 17, 2011
Approved
Time to decision
114 days
Received Apr 25, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P110020
- Device name
- COBAS 4800 BRAF V600 MUTATION TEST
- Applicant
- Roche Molecular Systems, Inc.
- Applicant location
- Pleasanton, CA
- Received
- Apr 25, 2011
- Decided
- Aug 17, 2011
- Decision
- Approved
- Supplements
- 46 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Somatic gene mutation detection system (OWD)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE COBAS 4800 BRAF V600 MUTATION TEST. THIS DEVICE IS INDICATED FOR: THE COBAS 4800 BRAF V600 MUTATION TEST IS AN IN VITRO DIAGNOSTIC DEVICE INTENDED FOR THE QUALITATIVE DETECTION OF THE BRAF V600E MUTATION IN DNA EXTRACTED FROM FORMALIN-FIXED, PARAFFIN-EMBEDDED HUMAN MELANOMA TISSUE. THE COBAS 4800 BRAF V600 MUTATION TEST IS A REAL-TIME PCR TEST ON THE COBAS 4800 SYSTEM, AND IS INTENDED TO BE USED AS AN AID IN SELECTING MELANOMA PATIENTS WHOSE TUMORS CARRY THE BRAF V600E MUTATION FOR TREATMENT WITH VEMURAFENIB.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code OWD (Somatic gene mutation detection system).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Roche Molecular Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260045 · Decided Aug 28, 2026 · 233 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
K260047 · Decided Aug 28, 2026 · 233 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
- cobas® BV/CV510(k)
K260021 · Decided Jul 16, 2026 · 192 days after receipt
Device type: Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System (PQA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.